Skip to main content
. 2022 Dec 1;8(2):e10453. doi: 10.1002/btm2.10453

FIGURE 1.

FIGURE 1

PLE‐IL‐12‐NPs are able to selectively bind to tumor cells and remain localized to cell surfaces, releasing their IL‐12 cargo to activate T cells and other immune cells over a 24‐h period. These characteristics make PLE‐IL‐12‐NPs a strong candidate for safe and efficacious systemic delivery of IL‐12